AU2004260831A1 - Aryl dicarboxamides - Google Patents

Aryl dicarboxamides Download PDF

Info

Publication number
AU2004260831A1
AU2004260831A1 AU2004260831A AU2004260831A AU2004260831A1 AU 2004260831 A1 AU2004260831 A1 AU 2004260831A1 AU 2004260831 A AU2004260831 A AU 2004260831A AU 2004260831 A AU2004260831 A AU 2004260831A AU 2004260831 A1 AU2004260831 A1 AU 2004260831A1
Authority
AU
Australia
Prior art keywords
amino
alkyl
aryl
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004260831A
Other languages
English (en)
Inventor
Agnes Bombrun
Jean-Francois Pons
Dominique Swinnen
Russel J. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Publication of AU2004260831A1 publication Critical patent/AU2004260831A1/en
Assigned to LABORATOIRES SERONO SA reassignment LABORATOIRES SERONO SA Request for Assignment Assignors: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
AU2004260831A 2003-07-21 2004-07-20 Aryl dicarboxamides Abandoned AU2004260831A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03102236.1 2003-07-21
EP03102236 2003-07-21
US51782403P 2003-11-06 2003-11-06
US60/517,824 2003-11-06
PCT/EP2004/051558 WO2005011685A1 (fr) 2003-07-21 2004-07-20 Aryl-dicarboxamides

Publications (1)

Publication Number Publication Date
AU2004260831A1 true AU2004260831A1 (en) 2005-02-10

Family

ID=34924079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004260831A Abandoned AU2004260831A1 (en) 2003-07-21 2004-07-20 Aryl dicarboxamides

Country Status (12)

Country Link
US (1) US7365225B2 (fr)
EP (1) EP1656139B1 (fr)
JP (1) JP2006528157A (fr)
AT (1) ATE526964T1 (fr)
AU (1) AU2004260831A1 (fr)
CA (1) CA2529662A1 (fr)
DK (1) DK1656139T3 (fr)
ES (1) ES2375132T3 (fr)
PL (1) PL1656139T3 (fr)
PT (1) PT1656139E (fr)
SI (1) SI1656139T1 (fr)
WO (1) WO2005011685A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654247B1 (fr) * 2003-07-21 2010-01-20 Merck Serono SA Alkynylaryl-carboxamides
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
CA2613458A1 (fr) * 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Composes presentant une activite au niveau des recepteurs de l'acide retinoique
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
CA2623327A1 (fr) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Compose heterocyclique azote et composition pharmaceutique le contenant
EP2786994B1 (fr) 2007-08-13 2017-11-22 Monsanto Technology LLC Procédé et compositions pour le contrôle de nématodes
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE202011111014U1 (de) * 2010-11-05 2018-05-02 Senomyx, Inc. Verbindungen, die als Modulatoren von TRPM8 nützlich sind
CN108473484B (zh) 2015-10-01 2021-06-29 弗门尼舍公司 可用作trpm8调节剂的化合物
AU2016342309B2 (en) 2015-10-23 2021-10-21 Vifor (International) Ag Ferroportin inhibitors
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069810A1 (fr) 1999-05-17 2000-11-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
PL359619A1 (en) * 2000-06-23 2004-08-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6972340B2 (en) * 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
DE10044792A1 (de) * 2000-09-11 2002-04-04 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung
EP1345890A1 (fr) * 2000-11-17 2003-09-24 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
AU2002223501A1 (en) * 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
WO2003024955A2 (fr) * 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Inhibiteurs a petites molecules de caspases
PL207295B1 (pl) 2002-01-29 2010-11-30 Serono Lab Podstawione pochodne metylenoamidowe , ich zastosowanie i sposób ich wytwarzania oraz kompozycja farmaceutyczna
EP1654247B1 (fr) * 2003-07-21 2010-01-20 Merck Serono SA Alkynylaryl-carboxamides

Also Published As

Publication number Publication date
US20060189583A1 (en) 2006-08-24
PT1656139E (pt) 2011-11-04
WO2005011685A1 (fr) 2005-02-10
PL1656139T3 (pl) 2012-03-30
US7365225B2 (en) 2008-04-29
CA2529662A1 (fr) 2005-02-10
SI1656139T1 (sl) 2011-12-30
ATE526964T1 (de) 2011-10-15
JP2006528157A (ja) 2006-12-14
EP1656139A1 (fr) 2006-05-17
ES2375132T3 (es) 2012-02-27
DK1656139T3 (da) 2012-01-30
EP1656139B1 (fr) 2011-10-05

Similar Documents

Publication Publication Date Title
KR101194968B1 (ko) Ｐｔｐ 1-ｂ 저해제로서의 1,1’-(1,2-에틴디일)비스-벤젠유도체
CA2463615C (fr) Oxindoles hydrazides modulateurs des proteines tyrosines phosphatases (ptps)
EP1654247B1 (fr) Alkynylaryl-carboxamides
AU2003239296B2 (en) Substituted methylene amide derivatives as Modulators of Protein Tyrosine Phosphatases (PTPs)
AU2002342859A1 (en) Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPS)
CA2879053A1 (fr) Derives de thiophenes utiles dans le traitement du diabete
EP1656139B1 (fr) Aryl dicarboxamides
AU2003239296A1 (en) Substituted methylene amide derivatives as Modulators of Protein Tyrosine Phosphatases (PTPs)
JP2021515787A (ja) アミノ−ベンゾイソチアゾール及びアミノ−ベンゾイソチアジアゾールのアミド化合物
CA2879054C (fr) Derives d'imidazopyridine utiles dans le traitement du diabete
JP2006528157A5 (fr)
ES2366905T3 (es) Derivados de metilenamida sustituidos en calidad de moduladores de proteína tirosina fosfatasas (ptps).

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LABORATOIRES SERONO SA

Free format text: FORMER APPLICANT(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application